Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes
TreeFrog
April 23, 2024
Welcome to TreeFrog Therapeutics, where innovation meets hope in the realm of cell therapy.
Regenerative medicine is the future. We are the catalyzer to bring it into the now, working across the frontiers of physics and biology to advance cell therapies to clinical stage.
We aim to change the landscape of regenerative medicine, bringing effective cell therapies that are safe and efficient to millions of patients, through our own proprietary programs and by partnering with the best.
We are advancing a pipeline of cell therapies in regenerative medicine. Our lead program is in Parkinson’s Disease, on track for a first-in-human trial by 2026.
The therapy has the potential to be best-in-class due to the format - a 3D microtissue – that has unique efficacy and safety benefits such as enhanced cell survival post graft, effective dose control and superior quality control.
We have achieved several world firsts with C-Stem™, our proprietary biomimetic technology.
C-Stem™ is a technology platform that integrates GMP compliant encapsulation capable of generating over 1,000 capsules per second. This enables the seeding of up to 10-liter bioreactors, delivering 15 billion cells in a single batch.
Revolutionary
We have a clear purpose to bring cell therapy to all. Through the work we have achieved to date and our ambition, we have the potential and a clear roadmap to become a leader in induced Pluripotent Stem Cells (iPSCs) regenerative medicine.
In order to create maximum value while advancing a pipeline of cell therapies in regenerative medicine, we adapt our approach with a unique business model.
Proprietary pipeline
We are currently in the process of developing a pipeline of cell therapies to address the requirements of the most challenging diseases, with a primary program focused on Parkinson's disease and a discovery program dedicated to liver disease.
+130
Froggies in the company
Working tirelessly to transform the regenerative medicine landscape.
82million
raised in funds since 2018
This investment supports our pioneering stem cell research, powering the company to the future.
30 patent families
Embodying innovation in stem cell technology
We ensure cutting-edge technologies for our clients.
Discover the latest news and advancements